Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
NCT05232838 · View on ClinicalTrials.gov ↗
Study Summary
The eShunt® System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.
Conditions Studied
Interventions
- DEVICE eShunt Implant
Study Locations (11)
New York
- University at Buffalo, — Buffalo
- NYU Langone Health — New York
- University of Rochester Medical Center — Rochester
- Montefiore Medical Center — The Bronx
Connecticut
- Yale University — New Haven
Florida
- Baptist Health — Jacksonville
Kansas
- University of Kansas Medical Center — Kansas City
Kentucky
- University of Kentucky Research Foundation — Lexington
Massachusetts
- Beth Israel Deaconess Medical Center — Boston
Rhode Island
- Rhode Island Hospital — Providence
Virginia
- Virginia Commonwealth University — Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2030-06-30 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05232838
The ClinicalTrials.gov registry entry for NCT05232838 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CereVasc, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Hydrocephalus appearing as the primary indexed condition, and to 1 intervention — of which eShunt Implant is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05232838 reports 11 study locations spanning 8 distinct geographic areas — top geographies include New York, Connecticut, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05232838 about?
NCT05232838 is a clinical study titled "US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus". The eShunt® System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt System is intended to sh...
What is the current status of trial NCT05232838?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2022-04-20. Estimated completion is 2030-06-30.
What conditions does trial NCT05232838 study?
This clinical trial studies the following conditions: Hydrocephalus, Hydrocephalus, Normal Pressure. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05232838?
The interventions under investigation include: eShunt Implant (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05232838?
This trial is sponsored by CereVasc, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05232838 being conducted?
This trial has 11 study locations across Connecticut, Florida, Kansas, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.